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Inhibition of autophagy as a treatment strategy for p53
wild-type acute myeloid leukemia
Hendrik Folkerts1, Susan Hilgendorf1, Albertus TJ Wierenga1,2, Jennifer Jaques1, André B Mulder2, Paul J Coffer3,4,
Jan Jacob Schuringa1 and Edo Vellenga*,1
Here we have explored whether inhibition of autophagy can be used as a treatment strategy for acute myeloid leukemia (AML).
Steady-state autophagy was measured in leukemic cell lines and primary human CD34+ AML cells with a large variability in basal
autophagy between AMLs observed. The autophagy flux was higher in AMLs classified as poor risk, which are frequently
associated with TP53 mutations (TP53mut), compared with favorable- and intermediate-risk AMLs. In addition, the higher flux was
associated with a higher expression level of several autophagy genes, but was not affected by alterations in p53 expression by
knocking down p53 or overexpression of wild-type p53 or p53R273H. AML CD34+ cells were more sensitive to the autophagy
inhibitor hydroxychloroquine (HCQ) than normal bone marrow CD34+ cells. Similar, inhibition of autophagy by knockdown of ATG5
or ATG7 triggered apoptosis, which coincided with increased expression of p53. In contrast to wild-type p53 AML (TP53wt), HCQ
treatment did not trigger a BAX and PUMA-dependent apoptotic response in AMLs harboring TP53mut. To further characterize
autophagy in the leukemic stem cell-enriched cell fraction AML CD34+ cells were separated into ROSlow and ROShigh subfractions.
The immature AML CD34+-enriched ROSlow cells maintained higher basal autophagy and showed reduced survival upon HCQ
treatment compared with ROShigh cells. Finally, knockdown of ATG5 inhibits in vivo maintenance of AML CD34+ cells in NSG mice.
These results indicate that targeting autophagy might provide new therapeutic options for treatment of AML since it affects the
immature AML subfraction.
Cell Death and Disease (2017) 8, e2927; doi:10.1038/cddis.2017.317; published online 13 July 2017
Acute myeloid leukemia (AML) is characterized by the
accumulation of immature blast cells in the bone marrow,
resulting in a disruption of normal hematopoiesis. The growth
advantage of leukemic cells over the normal hematopoietic
stem and progenitor cells (HPSC) is linked to a perturbation in
differentiation, metabolic and cell survival programming, as a
result of a number of genetic and epigenetic defects.1–3
Transcriptome studies have demonstrated that the expression
patterns of apoptotic and anti-apoptotic genes are significantly
different between AML CD34+ cells compared with CD34+
cells derived from healthy subjects.4,5
HPSC homeostasis requires macroautophagy (here
referred to as autophagy), which is an alternative cell survival
program involved in degradation of redundant organelles and
proteins.6–8 Autophagic flux in normal HSPC is most
prominent in the immature CD34+CD38− subfraction and
declines in more differentiated myeloid cells.9 Maintenance of
an adequate level of autophagy is essential for HPSC
homeostasis. Previous studies have shown that lentiviral
knockdown of the essential autophagy genes ATG5 and ATG7
results in impaired engraftment of cord blood (CB) CD34+ cells
in NSGmice.9,10 In addition, ATG7null or ATG5null mice develop
anemia and during long-term follow-up myelodysplasia.11–13
Recent studies in myeloid leukemia have suggested that in
AML the autophagy machinery might be disrupted, resulting in
intracellular accumulation of damaged mitochondria and
increased levels of reactive oxygen species (ROS), with
high ROS levels potentially promoting leukemic
transformation.12,14,15 In contrast, other studies have shown
that leukemic cells require functional autophagy during
leukemia maintenance.16–18 In addition, autophagy can be
an escape mechanism utilized by leukemic cells after
treatment with chemotherapeutics such as mTOR- and HDAC
inhibitors.19–25 Together, this suggests a greater dependency
of AML cells on these effector pathways. The aim of our study
was to determine whether inhibiting autophagy can provide an
additional means to impair leukemic stem cell (LSC) function-
ality. We demonstrated that AML CD34+ cells are more
susceptible for autophagy inhibition than normal CD34+ cells.
P53 is an important effector pathway in the observed apoptotic
responds, triggered by inhibition of autophagy.
Results
Leukemic cell lines with an increased autophagic flux are
more dependent on autophagy for their survival. During
autophagy double-membrane vesicles called autophago-
somes are formed, which fuse with lysosomes.6 It is
important not only to measure the steady-state number of
autophagosomes but also the turnover.26 This can be done
by staining cells with Cyto-ID, a dye that selectively labels
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autophagic vacuoles. The relative increase in Cyto-ID signal
after overnight incubation with hydroxychloroquine (HCQ) is
considered to be the autophagy flux.9 In the tested cell lines
autophagy flux varied, HL60 cells had a significantly lower
flux as compared with OCIM3, MOLM13, KG1A and NB4
cells (Figures 1a, b and Supplementary Table S1). These
results were confirmed by using alternative methods for
analyzing autophagy flux. First, cell lines expressing GFP-
ATG8/LC3 were treated with or without the autophagy
inhibitor Bafilomycin-1A (BAF). The relative accumulation of
GFP-ATG8/LC3 puncta upon BAF treatment is indicative for
the level of autophagy flux (Supplementary Figure S1A).
Representative pictures of GFP-ATG8/LC3 puncta accumu-
lation in NB4 cells are depicted in Supplementary
Figure S1B. In addition, autophagic flux was determined by
tandem fluorescent-tagged LC3 reporter (Figure 1c) and
relative accumulation of LC3-II by western blotting (Figure 1d,
Supplementary Figures S1C and D). To confirm that the
observed autophagic flux measurements in combination with
HCQ where autophagy specific, HL60 and NB4 cells were
pre-treated with 5 mM 3-methyladenine (PI3K inhibitor) or
10 μM SBI-0206965 (ULK1 inhibitor), thereby blocking
autophagosome formation. By inhibiting PI3K or ULK1 a
near complete block in HCQ-dependent LC3-II accumulation
was observed underscoring an autophagy-specific mechan-
ism (Supplementary Figures S1E and F).
To validate whether the observed autophagic flux was
functionally relevant, the HL60, MOLM13, OCIM3 and NB4
cell lines were transduced with lentiviral shRNAs, to knock-
down the essential autophagy genes ATG5 (shATG5) or ATG7
(shATG7). Each shRNA was selected from a set of five
individual shRNAs, which were extensively tested as
described previously.9 The knockdown efficiency for shATG5
and shATG7 transduced leukemic cell lines was confirmed by
q-PCR (Supplementary Figure S2A). Lentiviral-mediated
knockdown of atg5 and atg7 resulted in a reduced accumula-
tion of GFP-ATG8/LC3 puncta after BAF treatment
(Supplementary Figure S2B), which coincided with a sig-
nificant reduction in survival (Figure 2b). To validate these
findings in an alternative manner, the cell lines were exposed
to different concentrations of HCQ during prolonged culture.
Survival and expansion after treatment with HCQ was
compared with CB CD34+ cells. CB CD34+ cells showed no
impairment in expansion when treated with 5 μM HCQ, while
20 μM HCQ significantly inhibited their expansion (Figure 2b
and Supplementary Figure S2C). The cell lines showed
variability in survival after HCQ treatment; notably those most
susceptible for HCQ had the highest level of autophagic flux
(Figures 1, 2b and Supplementary Figure S2C). The reduced
survival and proliferation after inhibition of autophagy was at
least in part due to increased apoptosis, as determined by
annexin-V staining (Figure 2c, red bars and Supplementary
Figure S2D). In MOLM13 and NB4 cells increased apoptosis
correlated with increased expression of p53 and its transcrip-
tional target genes BAX, PUMA and PHLDA3 (Supplementary
Figure S2E).
To investigate the potential role of p53 in the HCQ-induced
cell death, MOLM13 and NB4were transduced with a lentiviral
shRNAs, targeting TP53 (shp53; Supplementary Figure S2A).
The p53 status of used leukemic cell lines is indicated in
Supplementary Table S1. Compared with shSCR-transduced
cells, shp53-transduced cells did not show an apoptotic
Figure 1 Variation in autophagy flux between different leukemic cell lines. (a) Relative accumulation of autophagosomes after overnight treatment with 20 μMHCQmeasured
by staining with Cyto-ID in a panel of leukemic cell lines (N= 7). (b) Representative FACS plots showing mean fluorescent intensity of Cyto-ID, with or without HCQ treatment.
(c) mCherry/GFP ratio in a panel of leukemic cell lines transduced with mCherry-GFP-LC3. (d) Representative western blot of LC3-II accumulation after HCQ in cell lines, β-actin
was used as loading control. Error bars represent S.D.; *, ** or *** represents Po0.05, Po0.01 or Po0.001, respectively
Targeting autophagy in AML
H Folkerts et al
2
Cell Death and Disease
response to treatment with different HCQ concentrations
(Figure 2c, blue bars and Supplementary Figure S2F). More-
over, knockdown of p53 prevented HCQ-dependent expres-
sion of pro-apoptotic BAX and PUMA (Figure 2d and
Supplementary Figure S2G). In contrast, TP53null HL60 cells,
with low basal autophagy (Figure 1a), did not display induction
of apoptosis (data not shown) or a strong reduction of
expansion upon HCQ treatment (Figure 2b). Finally, p53wt
cell lines MOLM13 and OCIM3 were double transduced with
shSCR- or shP53-GFP in combination with shSCR- or
shATG5-mCherry. As expected, knockdown of ATG5 provided
a strong reduction in expansion, which could be rescued by
additional knockdown of p53. However, following longer
follow-up the rescue by shp53 gradually declined (Figure 2e
and Supplementary Figure S2H).
Variation in autophagy levels between different AMLs
independently of the differentiation status. Next, we
analyzed the expression of autophagy genes and the
functional consequences in patients AML CD34+ cells. In
total, 51 AML patients were studied; the clinical character-
istics of this cohort are described in Supplementary Tables
S2 and S3. For studying a homogeneous AML cell population
in vitro, the CD34+ AML subfraction was sorted and analyzed.
Quantitative PCR studies demonstrated that essential autop-
hagy genes ATG5 and ATG7 are more highly expressed in a
subset of AMLs compared with CD34+ normal bone marrow
cells (Supplementary Figure S3A and Supplementary
Table S4). In addition, expression levels of autophagy genes
in AML and normal bone marrow were assessed in publicly
available expression data sets (Bloodspot expression
database27). Expression of a subgroup of autophagy genes
was higher in AML compared with normal HSCs, especially
genes involved in the mTOR-dependent ULK1 complex or
LC3 lipidation (Supplementary Figure S3B).27 To investigate
the functional consequences of this observation, we mea-
sured autophagy flux in AML CD34+ cells (n=51). A large
variability in autophagic flux was observed, comparable to the
results in cell lines (Figures 1, 3a and Supplementary
Figure S3C). No difference in autophagic flux was observed
Figure 2 Sensitivity for inhibition of autophagy in leukemic cells. (a) Normalized GFP percentages in leukemic cell lines transduced with shSCR-GFP, shATG5-GFP or
shATG7-GFP and cultured for 12 days. (b) Cumulative growth of leukemia cell lines and cord blood-derived CD34+ cells cultured for 10 days in the presence of 0, 5 or 20 μM
HCQ. (c) Percentage of Annexin-V-positive cells in shSCR or shp53 transduced MOLM13 cells, at day 4 after treatment with different concentrations of HCQ. (d) Quantitative RT-
PCR for BAX and PUMA in shSCR and shP53 transduced MOLM13 cells, treated with 20 μM HCQ for 4 days. (e) Cell expansion in time of MOLM13 cells double transduced with
shp53-GFP or shSCR-GFP in combination with shSCR-mCherry or shATG5-mCherry. The transduced cells were cultured for 12 days. Error bars represent S.D.; *, ** or ***
represents Po0.05, Po0.01 or Po0.001, respectively
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between the AML CD34+CD38− fraction compared with more
mature CD34+CD38+ fraction (n= 8; Supplementary
Figure S3D). Also, no difference was observed between
bone marrow and peripheral blood-derived AML cells (Supp-
lementary Figure S3E). Since AML is clinically a hetero-
geneous disease, autophagic flux was correlated to a number
of clinical relevant parameters, including the French–Amer-
ican–British classification (FAB), cytogenetics, molecular
markers and prognostic risk classification. No significant
difference in autophagy flux was shown between AML cells
belonging to the myeloid (M1–M2) or monocytic lineages
(M4–M5) (Supplementary Figure S3F). Cytogenetic analysis
revealed that AML patients with complex cytogenetic
abnormalities had the highest level of autophagy
(Figure 3b). In line with these results, expression of many
core autophagy genes was higher in AMLs with complex
karyotype compared with other AML subgroups
(Supplementary Figure S3B).27 When patients were categor-
ized according to ELN criteria28 in favorable, intermediate-I,
-II and adverse-risk groups, AML CD34+ cells belonging to
adverse-risk group had significantly higher levels of autop-
hagy compared with the intermediate- or favorable-risk AMLs
(Figure 3c). AMLs with mutations in TP53, which were all
classified as adverse-risk, had higher autophagic flux
(Figure 3d). In contrast, no differences in autophagy levels
were observed in AMLs harboring mutations in FLT3, NPM1,
IDH1/2, DNMT3A or CEPBA genes (Figure 3d).
To study the functional relevance of the autophagic flux for
survival, AML CD34+ cells were treated with 0, 5, 10 or 20 μM
HCQ for 72 h. The survival of AML cells was measured over
time and compared with normal bone marrow CD34+ cells
treated in a similar manner. As shown in Figure 4a, a
significant dose-dependent increase in sensitivity to HCQ
was observed in AML CD34+ compared with CD34+ cells
isolated from healthy controls (20 μM HCQ, 23.0± 3.1%
versus 42.5± 6.6% surviving cells, respectively, Po0.05).
Similarly, inhibition of autophagy in AML CD34+ cells resulted
in a dose-dependent increase in apoptosis as measured by
annexin-V positivity (Figure 4b and Supplementary
Figure S4A). In contrast to observations in leukemic cell lines,
no correlation was observed between the level of autophagic
flux and the sensitivity for HCQ. To validate the dependency on
autophagy in an alternative manner, AML CD34+ (n=5) were
transduced with either shATG5 or shATG7, and expansion on
an MS5 stromal layer was measured over time. A strong
decrease in cell expansion was observed in response to ATG5
or ATG7 downregulation in comparison with shSCR-
transduced AML cells (Figure 4c, Supplementary Figures
S4B and C).
Inhibition of autophagy triggers a p53-dependent
increase in apoptosis in AML CD34+ cells. Since we
observed that some AML CD34+ samples were less sensitive
for HCQ, we compared the sensitivity of wild-type TP53
(TP53wt) to those harboring TP53 mutations (TP53mut). As
shown in Figure 4a, TP53mut AML CD34+ cells (n=5,
Supplementary Table S3) were significantly less sensitive at
5, 10 or 20 μM HCQ compared with TP53wt cells (20 μM
HCQ, 71.8.±9.8% versus 23.0± 3.1% surviving cells,
respectively, Po0.0001). To characterize further differences
Figure 3 Variation in autophagy levels between different AMLs, independent of the differentiation status. (a) Left panel, for autophagic flux measurements (relative Cyto-ID
accumulation) in AML CD34+ blasts (n= 51), AML CD34+ cells were cultured for 3 days on MS5 stromal layer before overnight incubation with 20 μM HCQ. Right panel,
representative FACS plot showing the accumulation of Cyto-ID after treatment with HCQ. (b) Autophagy flux in AMLs with normal karyotype versus complex cytogenetic
abnormalities. (c) Autophagy flux in AMLs according to the various ELN risk groups. (d) Autophagy flux in AML CD34+ cells according to commonly mutated genes in AML. Error
bars represent S.D.; *, ** or *** represents Po0.05, Po0.01 or Po0.001, respectively
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in responsiveness between TP53wt and TP53mut patient-
derived cells, AML CD34+ TP53wt cells (n= 5) or TP53mut
cells (n= 4) were treated with HCQ, and p53-dependent
transcriptional target gene expression patterns were ana-
lyzed. In patients with TP53 mutations both homozygous and
heterozygous TP53 mutations were observed. Basal levels of
BAX, PUMA and p21 mRNA expression were lower in
TP53mut cells compared with TP53wt AML CD34+ cells.
Interestingly, in contrast to TP53wt cells, expression levels of
pro-apoptotic BAX and PUMA were not increased upon HCQ
Figure 4 Inhibition of autophagy triggers apoptosis in primary AML CD34+ cells. (a) Survival of normal bone marrow (NBM) CD34+, TP53wt AML CD34+ or TP53mut AML
CD34+ cells were cultured for 3 days on an MS5 stromal layer before treated with 5, 10 or 20 μM HCQ for 48 h. (b) Quantification of Annexin-V percentages in AML (n= 9) after
treatment with 5 or 20 μM HCQ. (c) Normalized expansion of AML CD34+ cells transduced with shSCR, shATG5 or shATG7, cultured on an MS5 stromal layer. Error bars
represent S.D.; *, ** or *** represents Po0.05, Po0.01 or Po0.001, respectively
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treatment in TP53mut AML CD34+ cells, suggesting that the
apoptotic response was severely dampened in these cells
(Figure 5a). To confirm the role of p53 in the HCQ-mediated
effects, TP53wt AML cells were co-treated with Nutlin-3A,
which stabilizes p53 by inhibition of MDM2. The combined
used of HCQ and Nutlin-3A significantly enhanced the
apoptotic effect compared with HCQ alone in TP53wt AML
CD34+ cells (Figure 5b). To verify these findings in an
alternative manner p53wt and mutant TP53R273H were over-
expressed in p53wt OCIM3 leukemic cells and subsequently
treated them with increasing concentrations of HCQ.
TP53R273H is described as gain-of-function mutation asso-
ciated with drug resistance. Overexpression of p53wt
enhanced the HCQ-dependent apoptotic response and
resulted in reduced survival compared with control
(Supplementary Figure S5A). In contrast, overexpression of
mutant TP53R273H rendered the AML cells more resistant to
HCQ treatment (Figure 5c and Supplementary Figure S5A).
However, overexpression of p53wt or TP53R273H in OCIM3
cells did not affect the autophagic flux as determined by Cyto-
ID (Supplementary Figure S5B). Comparable results were
obtained in the context of p53 knockdown in OCIM3 and
MOLM13 cells. No change in accumulation of LC3-II or
sqstm1/p62 was observed. (Figure 5d and Supplementary
Figure S5C). Also in normal CB CD34+ cells overexpression
of p53wt or TP53R273H did not affect the levels of autophagy
(relative Cyto-ID values; control 2.3± 0.4-fold, p53wt
2.2±0.6-fold or p53mut 2.1± 0.3-fold). Together, these results
indicate that inhibition of autophagy initially triggers a p53-
dependent apoptotic response, which is severely dampened
in AML CD34+ cells harboring mutations in the TP53 gene
irrespective of the autophagy flux.
AML CD34+ROSlow cells have a higher autophagic flux.
We did not observe differences in autophagy in more
immature CD34+CD38− versus more mature CD34+CD38+
blast (Supplementary Figure S3D). To determine whether
there is still variability in the level of autophagy within the AML
CD34+ fraction, we separated the AML CD34+ subfraction
into ROSlow and ROShigh cells. A recent study has shown that
ROSlow AML cells are enriched for LSCs by using in vitro as
well as in vivo assays.29 We identified the ROSlow and
ROShigh AML CD34+ by sorting the 15% low and high
subfractions based on the CellROX mean fluorescent
intensity (MFI) in the AML CD34+ cell population
(Figure 6a). A significant distinction in CellROX MFI was
demonstrated in AML CD34+ (n= 14) ROShigh compared with
ROSlow cells (Figure 6a and Supplementary Figure S6A).
Sorted ROSlow cells exhibited more immature morphology, as
determined by the relative size of the nucleus to the
cytoplasm. Representative pictures of AML cells from sorted
ROSlow and ROShigh AMLs are shown in Supplementary
Figure S6B. Interestingly, ROSlow cells maintained a sig-
nificantly higher autophagic flux compared with the ROShigh
AML CD34+ cells, within the same patient sample, as
determined by Cyto-ID (Figures 6b, Po0.01 and
Figure 5 TP53 mutant AMLs are resistant for HCQ-induced apoptosis. (a) Gene expression of BAX and PUMA determined by quantative RT-PCR in TP53wt (n= 4) or
TP53mut (n= 4) AMLs. AML CD34+ cells were cultured for 3 days on an MS5 stromal layer before 72 h incubation with 20 μM HCQ. (b) Percentage of Annexin-V-positive cells in
TP53wt AML CD34+ cells treated with 5 or 20 μM HCQ in conjunction with or without Nutlin-3A. (c) Cell counts of OCIM3 cells transduced with pRRL-mBlueberry, pRRL-P53mut-
mBlueberry or pRRL-P53wt-mBlueberry, treated with different concentrations of HCQ. (d) Western blot showing LC3-II, sqstm1/p62 and p53 protein expression in OCIM3 cells
transduced with shSCR or shP53 treated overnight with or without 20 μM HCQ. Error bars represent S.D.; * represents Po0.05
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Supplementary Figure S6C). In addition, sorted ROSlow and
ROShigh subfractions AML CD34+ cells were treated over-
night with HCQ and subsequently accumulation LC3-II was
detected by western blotting. A higher accumulation was
shown in the ROSlow AML cells (Supplementary Figure S6D).
qRT-PCR analysis demonstrated a significantly higher
expression of BCL-2 in the ROSlow AML CD34+ cells
(Supplementary Figure S6E). In addition, higher expression
of the autophagy genes Beclin-1 and MAP1LC3A and the
autophagy regulator FOXO3A was observed in ROSlow AML
CD34+ cells compared with the ROShigh CD34+ cells
(Figure 6c).30,31 In contrast, expression of other key
autophagy genes and major ROS scavengers such as
SOD1, SOD2 and Catalase was comparable between both
fractions (data not shown).
To evaluate growth characteristics and the functional
relevance of autophagy in the distinct AML CD34+ subpopula-
tions (n=4), FACS-sorted AML CD34+ ROSlow and ROShigh
cells were cultured on MS5 bone marrow stromal cells. The
ROSlow AML CD34+ cells exhibited long-term expansion in
comparison with the ROShigh CD34+ cells (week 5; ROSlow 7.1-
fold±2.1 versus ROShigh 1.6-fold±0.4 (n=6, P≤0.05)). Next,
ROSlow and ROShigh fractions were treated with 5 or 20 μM
HCQ for 48 h and survival was determined (Figure 6d). ROSlow
cells were more sensitive to HCQ treatment compared with
ROShigh cells, correlating with increased apoptosis
(Supplementary Figure S6F). Since mitochondria have an
important role in ROS production, we evaluated mitochondrial
mass in AML CD34+ cells in both the ROSlow and ROShigh
subfractions. AML CD34+ ROSlow cells had a lower mitochon-
drial mass compared with ROShigh AML CD34+ cells (n=11,
Po0.0001; Supplementary Figure S6G).
Knockdown of ATG5 inhibits myeloid leukemia
maintenance in vivo. Based on the observations that
ATG5 and ATG7 knockdown reduce the expansion of AML
CD34+ cells in vitro, we determined whether this would also
occur in vivo. To exclude the possibility that the knockdown of
ATG5 or ATG7 affected cell migration, in vitro transwell
experiments were performed with the OCIM3 and MLOM13
cell line. In both cell lines, the SDF1-mediated migration was
not affected by the knockdown of ATG5 or ATG7
(Supplementary Figure S7D). Subsequently AML CD34+
cells were transduced with the shATG5 or shSCR-GFP and
Figure 6 Autophagy is higher in the ROSlow population of AML blasts. (a) Representative FACS plots showing CellROX staining in freshly isolated AML CD34+ cells. (b)
Relative Cyto-ID levels in ROShigh and ROSlow fractions of AML CD34+ cells (n= 11). (c) Gene expression of Beclin-1 and MAP1LC3A in freshly sorted AML CD34+ROShigh and
CD34+ROSlow cells. (d) Survival of FACS-sorted ROShigh and ROSlow AML CD34+ cells, cultured for 3 days on an MS5 stromal layer before treated for 48 h with different
concentrations HCQ. Error bars represent S.D., * or ** represents Po0.05 or Po0.01 respectively
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transplanted in immunodeficient NSG mice, as outlined in
Figure 7a. Transplanted AML blasts were at least 14% GFP
positive at the time of injection (Supplementary Figure S7A)
and ATG5 knockdown was confirmed by qRT-PCR
(Supplementary Figures S7B and C). The time for the onset
of leukemia was determined by measuring the percentage of
huCD45 in peripheral blood. While GFP levels for shSCR
remained stable at around ~ 15%, the contribution of the
shATG5-transduced cells to the engrafted AML cells was
significantly reduced, starting from week 6 (Figure 7b and
Supplementary Figure S7E). After killing, we observed high
engraftment levels in bone marrow, spleen and liver as
determined by the percentage of CD45. The contribution of
shSCR-GFP-transduced cells within the CD45 compartment
was stable around ~20% in all studied organs. On the
contrary, the percentage of shATG5-GFP-transduced cells
within the CD45 compartment was strongly decreased
(Figure 7c). The engrafted human AML cells were all of
myeloid origin, as determined by CD33 expression
(Supplementary Figure S7F). These results demonstrate
that autophagy is also essential for leukemia maintenance
in vivo.
Discussion
The aim of our study was to determine whether inhibiting
autophagy can provide an alternative means to impair LSC
functionality. AMLCD34+ cells were susceptible for autophagy
inhibition, which was demonstrated by in vitro and in vivo
experiments. In vitro studies indicated that the subfraction of
ROSlow AML CD34+ cells had the highest autophagic flux and
weremore susceptible to HCQ treatment when compared with
ROShigh AML CD34+ cells. The AML ROSlow subfraction is
further characterized by lower mitochondrial mass and
elevated BCL-2, FOXO3A and Beclin-1 expression. These
results are of interest since a previous study has shown that
ROSlow AML CD34+ cells are enriched for LSCs.29 Similarly,
murine ROSlow HSPC are enriched for stem cells.32 In the
studied AMLs, the autophagy flux was most pronounced in
adverse-risk group with complex cytogenetic abnormalities
thath are frequently associated with TP53 mutations. Tran-
scriptome data revealed a significant higher expression of
autophagy genes in the AML subgroup with complex
karyotype. It has been suggested that the adverse-risk AMLs
have a higher number of LSCs compared with favorable-risk
AMLs, which might have consequences for the measured
level of autophagy.33,34 Although the high autophagy flux was
connected with complex karyotype and TP53 mutations,
modulation of p53 in normal or leukemic cells by p53
knockdown or ectopic overexpressing p53mut did not affect
the autophagy flux. Therefore, the high autophagic flux in the
AML CD34+ subfraction might be an intrinsic property as
consequences of an adaptive response to constitutive meta-
bolic stress linked to the (epi)genetic mutations.
Inhibition of autophagy in leukemic cells might limit nutrient
availability in cells, causingmetabolic stress and consequently
apoptosis. Moreover, impaired autophagy in hematopoietic
cells has been associated with increased mitochondrial
mass, resulting in ROS accumulation.8,9,15 In turn, excessive
ROS has been shown to cause oxidative DNA damage
and consequently premature senescence and HSC
exhaustion.35,36 Our study indicates that the p53 pathway,
irrespective of the level of autophagy, is an important effector
Figure 7 Knockdown of ATG5 in AML CD34+ blasts results in impaired engraftment. (a) Experimental set-up. (b) Left panel: engraftment levels measured by huCD45%. Right
panel: the GFP% within huCD45+ population. Each dot represents data from a single mouse, shSCR (N= 4) and shATG5 (N= 5). (c) Engraftment (percentage huCD45) at time
of killing in bone marrow, spleen and liver and the GFP% within the huCD45+ population. (d) Summarizing Model: LSCs are enriched in the ROSlow fraction of AML blasts. ROSlow
cells maintain a higher basal autophagy flux and have a lower mitochondrial mass compared with ROShigh cells. Right part: short-term genetic or pharmaceutical Inhibition of
autophagy triggered a p53-dependent apoptotic response in p53 wild-type AMLs, which was severely dampened in p53 mutant AMLs. Error bars represent S.D.; * or ***represents
Po0.05 or Po0.001, respectively
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pathway for cell death induced by autophagy inhibition, which
has consequences for AMLs with TP53 mutations. TP53mut
AML cells show decreased sensitivity for short-term treatment
with HCQ and an impaired upregulation of the apoptotic genes
PUMA and BAX, indicating that the initial apoptotic response
in these cells is strongly impaired.
In view of these findings co-treatment with autophagy
inhibitorsmight only be a promising approach for the treatment
of TP53wt AMLs. Similar observations have been made in
chronic myeloid leukemia (CML).37,38 The combination of
tyrosine kinase inhibitors in combination with autophagy
inhibitors resulted in more effective elimination of CML stem
cells.39 This approach might also be attainable in vivo since
various studies in patients with solid tumors have shown that
high-dose HCQ can block autophagy in vivo.17,23,40,41
Currently, a second generation of HCQ-derived autophagy
inhibitors are being developed, which are more potent in
inhibition of autophagy,42,43 thereby increasing the clinical
applicability of autophagy inhibition.
In the present study we focused mainly on the role of
autophagy during leukemia maintenance. This might be
distinct from the role of autophagy during leukemia initiation,
as consequences of the emergence of (epi)genetic
mutations.2,3 Model systems for leukemia and solid tumors
have shown that during malignant transformation, autophagy
might be reduced as a result of mutagenesis, resulting in
accumulation of mitochondria, ROS-mediated DNA damage
and activation of NF-κB signaling.12,13 Likewise, U2AF35
mutations in myelodysplastic syndrome cause abnormal
processing of ATG7 pre-mRNA and consequently reduced
expression of ATG7.44 In addition, a recent study reported
mutations of autophagy genes in a small fraction of MDS
patients, which might be contributive to malignant
transformation.45
In summary, our results demonstrate that autophagy has a
critical function for AML maintenance and that inhibition of
autophagy might be a promising therapeutic strategy in a
subgroup of AML patients (summarizing model, Figure 7d).
Material and Methods
Isolation and culture of human CD34+ cells. We obtained umbilical
cord blood (UCB) from full-term healthy neonates who were born at the Obstetrics
departments of the Martini Hospital and the University Medical Center Groningen
(Groningen, the Netherlands). Informed consent was obtained to use UCBs and
patients' AML blasts derived from peripheral blood cells or bone marrow in
accordance with the Declaration of Helsinki; the protocols were approved by the
Medical Ethics Committee of the University Medical Center Groningen (UMCG).
Mononuclear cells were isolated from UCB, or peripheral blood or bone marrow
from AML patients by Ficol density centrifugation, and CD34+ cells were
subsequently isolated with the autoMACS pro-separator (Miltenyi Biotec,
Amsterdam, the Netherlands).
Cell culture. Primary AML, normal bone marrow or CB-derived CD34+ cells
were cultured in suspension or in T25 flasks pre-coated with MS5 stromal cells in
Gartners medium: Alpha-MEM (Lonza, Leusden, the Netherlands) supplemented
with 12.5% FCS and 12.5% horse serum (Sigma-Aldrich, Saint Louis, MO, USA),
1% penicillin/streptomycin (PAA Laboratories, Dartmouth, MA, USA), 1 μM
hydrocortisone (Sigma-Aldrich), 57.2 mM β-mercaptoethanol and cytokines:
G-CSF, Human TPO agonist; Romiplostim (Amgen, Breda, the Netherlands) and
IL-3 (20 ng/ml each).46 For the autophagic flux AML CD34+ cells were cultured for
3 days on an MS5 stromal layer. Subsequently, the autophagic flux was determined
with cyto-ID. The relative increase in Cyto-ID signal after overnight incubation with
20 μM HCQ is considered to be the autophagy flux.9 The used concentration and
incubation time of HCQ for measuring autophagic flux was validated and is based
on maximal accumulation of autophagosomes, without affecting cell viability after
overnight incubation with HCQ. AMLs that did not expand were excluded from
analysis. The leukemic cell lines HL60, K562, THP1, OCIM3, MOLM13 and NB4
cells were cultured in RPMI 1640, supplemented with 10% FCS and 1% penicillin/
streptomycin. KG1A cells were cultured in IMDM (Lonza, Leusden, the Netherlands)
20% FCS and 1% penicillin/streptomycin.
Flowcytometry analysis. After isolation, cells were resuspended in PBS and
subsequently incubated for 30 min at 4 °C with anti-human CD19, CD34, CD38,
CD33 and CD45. After incubation, cells were washed and optionally incubated for
30 min at 37 °C using Cyto-ID Autophagy Detection dye (ENZ-51031-0050; Enzo
Life Sciences, Raamsdonksveer, The Netherlands). The cells were subsequently
washed and analyzed by flow cytometric analysis (FACS). (Additional information
can be found in Supplementary Table S5.) All data were analyzed using FlowJo
(Tree Star, Ashland, OR, USA) software.
Apoptosis, ROS and mitochondrial mass measurements.
Apoptosis was quantified by staining with APC-conjugated Annexin-V (Beckton
Dickinson, Franklin Lakes, NJ, USA) according to the manufacturer’s protocol. ROS
analyses were performed by means of CellROX deep red (APC) or CellROX green
(FITC; Life Technologies, Landsmeer, the Netherlands), according to the
manufacturer’s protocol. Mitochondrial mass was determined with Mitotracker
staining (Life Technologies), according to the manufacturer’s protocol. Apoptosis,
CellROX and mitochondrial mass were analyzed by FACS.
Virus production and transduction of CD34+ leukemic cells.
shATG7 (TRCN0000007586; Sigma-Aldrich) and shATG5 (TRCN0000151474;
Sigma-Aldrich) and shP53 vectors were cloned and extensively validated, as
previously described.9 An shRNA sequence that does not target human genes
(referred to as scrambled) was used as a control. TP53R273H or TP53wt were
generated by PCR amplification from cDNA obtained from MDA-MB-468 or
MOLM13 cells, respectively. Amplified cDNA was subsequently cloned into
pRRL-IRES-mBlueberry vector,47 using EcoR1 restriction sites. Lentiviral virions
were produced by transient transfection of HEK 293 T cells with pCMV and VSV-G
packing system using Polyethylenimine (Polyscience Inc. Eppelheim, Germany) or
FuGENE (Promega, Leiden, the Netherlands). Retroviral virions containing pBABE-
puro-mCherry-EGFP-LC3B (kind gift from Prof. Andrew Thorburn, Department of
Pharmacology, University of Colorado Cancer Center) were produced by transient
transfection of HEK 293 T cells with VSV-G, pAmpho packing system and FuGENE.
Viral supernatants were collected and filtered through a 0.2-μm filter and
subsequently concentrated using Centriprep Ultracel YM-50 centrifugal filters
(Millipore, Billerica, MA, USA). 0.5 × 106 CD34+ cells were seeded in Gartners
medium supplemented with cytokines (specified previously). Transduction was
performed by adding 0.5 ml of ~ 10 times concentrated viral supernatant to 0.5 ml of
medium in the presence of 4 μg/ml polybrene (Sigma-Aldrich). For retroviral
transfections, cells were transfected in retronectin-coated 24-well plates.
Quantitative real-time PCR. Quantitative RT-PCR was used to analyze the
mRNA levels of ATG5, Beclin-1, ATG8/LC3, VMP1, ATG10, ATG7, BAX, PUMA,
BCL-2 PHLDA3, p21, p53, FOXO3A, SOD1, SOD2 and Catalase. Total RNA was
isolated from at least 1 × 105 cells using the RNeasy kit (Qiagen, Venlo, the
Netherlands). RNA was reverse transcribed with iScript reverse Transcription kit
(Bio-Rad, Veenendaal, the Netherlands). The cDNA obtained was real-time
amplified, in iQ SYBR Green Supermix (Bio-Rad), with the CFX connect
Thermocycler (Bio-Rad). RPL27 and RPS11 were used as housekeeping genes.
The primer sequences are listed in Supplementary Table S6.
In vivo transplantation of AML CD34+ cells into NSG mice. For
transplantation, 12- to 13-week-old female NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/
SzJ) mice were purchased from the Central Animal Facility breeding facility at the
UMCG. Mouse experiments were performed in accordance with national and
institutional guidelines, and all experiments were approved by the Institutional
Animal Care and Use Committee of the University of Groningen (IACUC-RuG).
General aspects of these experiments have been described previously,9,48 and the
detailed experimental approach is described in the Supplementary Methods.
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Statistical analysis. An unpaired two-sided Student’s t-test was used to
calculate statistical differences. A P-value of o0.05 was considered statistically
significant.
Additional Materials and Methods can be found in the Supplementary Materials
and Supplementary Methods.
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